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Introduction 
In order to provide a point of reference for 
a rational approach to the therapy of acute uric-
emic nephropathy, the metabolic pathways 
leading to the production of uric acid will be 
I 
briefly reviewed . 
Uric acid is the end-product of adenine 
and guanine metabolism. Relevant to this dis-
cussion is the xanthine oxidase enzyme which 
catalyzes the conversion of hypoxanthine to 
xanthine and xanthine to uric acid. In children 
with acute leukemia the increasing production 
and subsequent destruction of white blood cells 
result in the rapid elevation of uric acid concen-
tration in the plasma, especially during treat-
ment with antineoplastic drugs. This in turn may 
lead to the development of acute hyperuricemic 
nephropathy. 1 - 4 
The uric acid deposition in the renal me-
dulla causes obstructive uropathies. This occur-
rence is not uncommon in children treated for 
reticuloendothelial malignancies, sarcoma and 
acute lymphocytic leukemia. 
Incidence 
The work done at the National Cancer In-
stitute of the National Institutes of Health (NIH) 
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showed that 6 out of 5 7 patients with acute leu-
kemia developed uric acid nephropathy.4 The 
treatment had consisted of methotrexate, 6-
mercaptopurine, hydrocortisone and cortisone. 
The duration of treatment before the clinical on-
set of hyperuricemic nephropathy was from 
three to six days. The maximum elevation of 
white cells was 11,800 to 18,000 per mm3 ; of 
uric acid from 1 7 to 71 ; and of BUN from 51 to 
212 mg/1 OOml. 
A number of subsequent reports have am-
ply confirmed and extended these observations 
of Frei et al,4 and a number of conclusions can 
be made. 
Risk Factors 
Uric acid nephropathy is more prone to 
develop in the treatment of acute lymphocytic 
leukemia when the following conditions are 
present: elevation of white blood cells to more 
than 20,000/ mm3 , marked adenopathy, espe-
cially in the mediastinum, and massive hepa-
tosplenomegaly. 
The histology of severe uric acid nephrop-
athy includes intratubular hydronephrosis and 
infarction from uric acid obstruction5 ·6 ; the 
milder and more common form of uric acid ne-
phropathy shows marked renal enlargement 
produced by the intense interstitial leukemic in-
filtration; the glomeruli and tubules are intact. 
There is a good correlation between the kidney 
and liver size in patients with less than 5% leu-
kemic infiltration of these organs. 4 
Treatment 
The first two modes of treatment rely on 
the provisions of a more favorable situation for 
the deposition of uric acid which is reduced 
when the urinary pH is made alkaline in excess 
of 6, beyond which point the solubility of uric 
acid is increased in an exponential fashion . 
To insure a good urine output , intravenous 
5% dextrose/water is administered at a rate of 
3000 ml/m 2 /day. To promote uric acid solubil-
ity and therefore enhance excretion, the urine 
may be made alkaline by administering intra-
venous sodium bicarbonate at a dosage calcu-
lated to elevate the serum bicarbonate by 1 0 
mEq/liter, and/or the use of a carbonic anhy-
drase inhibitor acetazolamide to block the renal 
tubular reabsorption of bicarbonate. The aims 
of these general measures are to achieve a uri-
nary pH in excess of 6 and a urine volume in ex-
cess of 60 ml/m 2 /hour. 
If the urine output is less than 60 ml/m 2 / 
hour after rehydration, mannitol (25% aqueous 
solution) is given initially over a 5- to 1 0-minute 
period in a test dose of 6 .25 gm in children 
weighing less than 30 kg and 12.5 gm in chil-
dren weighing over 30 kg . If diuresis ensues, 
additional mannitol is administered in the same 
dose every 6 hours to achieve a urine output of 
at least 60 ml/m 2 /hour. 
It is important to obtain and record urine 
volume, pH, body weight, vital signs, blood uric 
acid, electrolytes, BUN, and calcium concentra-
tions every 1 2 to 24 hours. 
Normal glomerular filtration rates are 
achieved within 2 to 1 4 days of treatment of hy-
peruricemia with fluids , bicarbonate and aceta-
zolamide. 7 
Allopurinol 
Allopurinol (1 0 mg/kg/day initial oral 
dose) is a useful drug for the treatment of hyper-
uricemia. 7 ·8 Allopurinol is a potent inhibitor of 
xanthine oxidase for which it is also a substrate. 
Although the incidence of side effects is 
very low, the potential complications of allopuri-
nol treatment should always be kept in mind . 
These include skin and blood dyscrasias, ma-
laise, fever, complaints of nausea, headache, 
vomiting, vertigo, drowsiness and gastric irrita-
tion, muscle ache, elevation of SGOT /SGPT, 
leLJcocytosis, leucopenia and, rarely, peripheral 
neuritis and bone marrow depression . 
Special Therapy 
The rapid removal of uric acid can be 
achieved by either peritoneal dialysis or hemo-
dialysis. 
Peritoneal dialysis removes uric acid at a 
rate of 1 5 ml/min, but hemodialysis is at least 
five times more effective.1·2 The decision on 
when to institute these procedures is a clinical 
one and is based on the physician 's past expe-
rience and the patient's status . One example of 
this complex clinical decision is shown in the 
Figure . 
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Figure--Acute uric acid nephropathy and treatment with 
hemodialysis is illustrated in the clinical course of a 1 4-year-
old white boy. 
Acute uric acid nephropathy occurred at the time 
of leukemic relapse. Diuresis did not occur despite 
all the general treatment procedures. Peritoneal 
dialysis was only partially successful in the re-
moval of 4 gm of uric acid in 24 hours without 
lowering the serum uric acid concentration. Hemo 
dialysis was instituted and removed over 1 7 gm of 
uric acid resulting in a decrease of serum uric acid 
from 87 to 29 mg/di. Immediately following dial-
ysis, he was given 25 gm of intravenous mannitol 
and was started on allopurinol. However, anuria 
persisted and a second course of hemodialysis 
was performed for 6 hours, resulting in a decrease 
of serum uric acid from 46 to 19 mg/di. Just be-
fore the completion of the dialysis, he voided 340 
ml of urine and the output remained adequate 
thereafter aided by good fluid and conservative 
medical management. 
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The use of hemodialysis is dependent on 
machine availability and the existence of a spe-
cially trained nephrology team consisting of 
dialysis technicians, nurses, surgeons, and 
nephrologists. Peritoneal dialysis requires less 
technical hardware and can be initiated more 
promptly by the nephrologist; whereas, before 
hemodialysis can be initiated, vascular access 
and somewhat extensive preparations are 
needed, especially in small children in the 2- to 
3-year age group, where uric acid nephropathy 
more commonly occurs. 
There is a relationship between the days 
of oliguria before dialysis has been started and 
the number of days until diuresis begins2 which 
has been taken as an indication for the early in-
stitution of either of these special procedures 
within a day or two of anuria and/or rapidly ris-
ing serum uric acid concentrations. 
Summary 
Hyperuricemic acute nephropathy occurs 
in 1 0% of patients with leukemia; the intrarenal 
uric acid deposition results in obstructive uro-
pathy. 
The clinical findings which point to the 
likelihood of renal damage are: first, an initial 
white blood cell count in excess of 20,000/ 
mm3 ; second, marked adenopathy especially in 
the mediastinum; and third, the presence of 
massive hepatosplenomegaly. The aim of gen-
eral treatment with fluids and renal alkalinization 
is to promote uric acid solubility and output by 
maintaining urine pH in excess of 6 and urine 
volume in excess of 60 ml/m 2 / hr. The discov-
ery and clinical use of allopurinol, an analogue 
of hypoxanthine and an inhibitor as well as a 
substrate of the enzyme xanthine oxidase, is 
central to the control of hyperuricemia. Allopuri-
nol , as well as its metabolic end-product, allo-
xanthine, acts at the terminal steps of uric acid 
metabolism to reduce the production of uric 
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acid and in conjunction with the other general 
medical therapy, contributes to the reversal of 
the hyperuricemia. 
Finally, the special extrarenal procedures 
of peritoneal dialysis and hemodialysis can rap-
idly, efficiently and safely remove the uric acid 
from the body. The sooner one initiates either of 
these procedures, the earlier diuresis begins. 
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